The ergosterol-synthesis inhibitor posaconazole proved ineffective at eliminating Trypanosoma cruzi DNA from the blood of patients with chronic Chagas’ disease, according to a report published...
ALBUQUERQUE – A single buccal application of acyclovir delayed recurrence of herpes labialis by an average of 100 days, compared with placebo, according to the results of a randomized, double-blind,...
CHICAGO – The investigational "3D" combination of oral antiviral drugs achieved a cure rate that was nothing short of sensational in the phase III PEARL-II trial involving noncirrhotic...
CHICAGO – More and more elderly people are getting infected with Clostridium difficile, and many get readmitted to the hospital after initial treatment for this potentially deadly diarrheal...
Physician leaders are voicing support for a proposed federal law that aims to reduce litigation against doctors, lower health care costs, and establish more fairness in the analyzing of malpractice...
CHICAGO – Two old workhorses in the treatment of hepatitis C are being put out to pasture – interferon and ribavirin.
Newer, less toxic oral regimens can cure more patients with fewer side effects,...
CHICAGO – An experimental triple-drug regimen with or without ribavirin cured more than 90% of 724 previously untreated patients with hepatitis C genotype 1 who did not have cirrhosis.
And it was...
VANCOUVER, B.C. – Dr. Daniel C. Payne has been investigating the Middle East Respiratory Syndrome coronavirus since the first case was reported in the Arabian Peninsula nearly 2 years ago.
An...
CHICAGO – Treating patients with hepatitis C virus genotype 1a or 1b with 12 weeks of an experimental interferon-free, triple-drug oral regimen produced good sustained virologic response rates with...
CHICAGO – Oral sofosbuvir and ribavirin given for 12 weeks produced a sustained virologic response in 93% of 250 patients with hepatitis C virus genotype 2 and in 85% of patients with genotype 3...
